HIV-1 Mutational Pathways Under Multidrug Therapy
Author Information
Author(s): Lawyer Glenn, Altmann André, Thielen Alexander, Zazzi Maurizio, Sönnerborg Anders, Lengauer Thomas
Primary Institution: Max Planck Institute for Informatics
Hypothesis
Can understanding mutational pathways improve therapy decisions for HIV-1 treatment?
Conclusion
Including the number of previous treatments and specific locations in the HIV genome can enhance the accuracy of therapy outcome predictions.
Supporting Evidence
- The strongest influence on developing NRTI resistance was having more than four previous therapies.
- Known NRTI resistance pathways were confirmed, and new pathways between NRTI and NNRTI resistance were identified.
- Viral resistance to therapy compounds did not significantly affect mutation hazards.
Takeaway
This study looks at how changes in the HIV virus can affect treatment success, especially when patients have had many previous therapies.
Methodology
A Cox proportional hazards model was used to analyze the relationship between preexisting mutations and the hazard of developing new mutations during therapy.
Potential Biases
Potential biases include dependence between genotyping and mutation outcomes, and non-random drug choices.
Limitations
The study is based on observational data, which may introduce biases related to treatment selection and genotyping practices.
Participant Demographics
{"age":{"mean":39.7,"std_dev":9.3},"gender":{"male":1054,"female":433},"previous_therapies":{"median":4,"range":"0-37"},"risk_groups":{"heterosexual":450,"homo_bisexual":367,"IVDA":372,"vertical_transmission":33,"blood_products":25,"other_unknown":245}}
Statistical Information
P-Value
p<0.01
Confidence Interval
{"lower_bound":0.06,"upper_bound":0.81}
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website